Transdermal pharmacology of small molecule cyclic C5a antagonists

Advances in Experimental Medicine and Biology

Volumn 586, Issue , 2006, Pages 329-345

  Proctor, Lavinia M ^a   Woodruff, Trent M ^a   Sharma, Prakirti ^a   Shiels, Ian A ^a   Taylor, Stephen M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84934442976     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/0-387-34134-X_22     Document Type: Conference Paper

References (39)

1. S.C. Makrides, Therapeutic inhibition of the complement system, Pharmacol Rev 50(1), 59-87 (1998).
2. J. Kohl, Anaphylatoxins and infectious and non-infectious inflammatory diseases, Mol Immunol 38(2-3), 175-187 (2001).
3. R.F. Guo and P.A. Ward, Role of C5a in inflammatory responses, Annu Rev Immunol 23, 821-852 (2005).
4. D.R. March, L.M. Proctor, M.J. Stoermer, R. Sbaglia, G. Abbenante, R.C. Reid, T.M. Woodruff, K. Wadi, N. Paczkowski, J.D. Tyndall, S.M. Taylor and D.P. Fairlie, Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity, Mol Pharmacol 65(4), 868-879 (2004).
5. A.K. Wong, A.M. Finch, G.K. Pierens, D.J. Craik, S.M. Taylor and D.P. Fairlie, Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a, J Med Chem 41(18), 3417-3425 (1998).
6. A.M. Finch, A.K. Wong, N.J. Paczkowski, S.K. Wadi, D.J. Craik, D.P. Fairlie and S.M. Taylor, Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a, J Med Chem 42(11), 1965-1974 (1999).
7. A. Short, A.K. Wong, A.M. Finch, G. Haaima, I.A. Shiels, D.P. Fairlie and S.M. Taylor, Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat, Br J Pharmacol 126(3), 551-554 (1999).
8. A.J. Strachan, T.M. Woodruff, G. Haaima, D.P. Fairlie and S.M. Taylor, A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats, J Immunol 164(12), 6560-6565 (2000).
9. M.S. Huber-Lang, N.C. Riedeman, J.V. Sarma, E.M. Younkin, S.R. McGuire, I.J. Laudes, K.T. Lu, R.F. Guo, T.A. Neff, V.A. Padgaonkar, J.D. Lambris, L. Spruce, D. Mastellos, F.S. Zetoune and P.A. Ward, Protection of innate immunity by C5aR antagonist in septic mice, FASEB J 16(12), 1567-1574 (2002).
10. T.M. Woodruff, A.J. Strachan, N. Dryburgh, I.A. Shiels, R.C. Reid, D.P. Fairlie and S.M. Taylor, Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat, Arthritis Rheum 46(9), 2476-2485 (2002).
11. T.M. Woodruff, T.V. Arumugam, I.A. Shiels, R.C. Reid, D.P. Fairlie and S.M. Taylor, A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease, J Immunol 171(10), 5514-5520 (2003).
12. D.W. Harkin, A. Romaschin, S.M. Taylor, B.B. Rubin and T.F. Lindsay, Complement C5a receptor antagonist attenuates multiple organ injury in a model of ruptured abdominal aortic aneurysm, J Vasc Surg 39(1), 196-206 (2004).
13. T.V. Arumugam, I.A. Shiels, T.M. Woodruff, R.C. Reid, D.P. Fairlie and S.M. Taylor, Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine, J Surg Res 103(2), 260-267 (2002).
14. T.V. Arumugam, I.A. Shiels, A.J. Strachan, G. Abbenante, D.P. Fairlie and S.M. Taylor, A small molecule C5a receptor antagonist protects kidneys from ischemia/ reperfusion injury in rats, Kidney Int 63(1), 134-142 (2003).
15. T.V. Arumugam, T.M. Woodruff, S.Z. Stocks, L.M. Proctor, S. Pollitt, I.A. Shiels, R.C. Reid, D.P. Fairlie and S.M. Taylor, Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats, J Hepatol 40(6), 934-941 (2004).
16. T.M. Woodruff, T.V. Arumugam, I.A. Shiels, R.C. Reid, D.P. Fairlie and S.M. Taylor, Protective effects of a potent C5a receptor antagonist on experimental acute limb ischemia-reperfusion in rats, J Surg Res 116(1), 81-90 (2004).
17. G. Girardi, J. Berman, P. Redecha, L. Spruce, J.M. Thurman, D. Kraus, T.J. Hollmann, P. Casali, M.C. Caroll, R.A. Wetsel, J.D. Lambris, V.M. Holers and J.E. Salmon, Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome, J Clin Invest 112(11), 1644-1654 (2003).
18. L. Bao, I. Osawe, T. Puri, J.D. Lambris, M. Haas and R.J. Quigg, C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist, Eur J Immunol 35(8), 2496-2506 (2005).
19. D.L. Sewell, B. Nacewicz, F. Liu, S. Macvilay, A. Erdei, J.D. Lambris, M. Sandor and Z. Fabry, Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist, J Neuroimmunol 155(1-2), 55-63 (2004).
20. T.M. Woodruff, S. Pollitt, L.M. Proctor, S.Z. Stocks, H.D. Manthey, H.M. Williams, I.B. Mahadevan, I.A. Shiels and S.M. Taylor, Increased potency of a novel C5a receptor antagonist in a rat model of inflammatory bowel disease, J Pharmacol Exp Ther 314(2), 811-817 (2005).
21. J.J. Berti and J.J. Lipsky, Transcutaneous drug delivery: a practical review, Mayo Clin Proc 70(6), 581-586 (1995).
22. J.D. Bos and M.M. Meinardi, The 500 Dalton rule for the skin penetration of chemical compounds and drugs, Exp Dermatol 9(3), 165-169 (2000).
23. A.C. Williams, B.W. Barry, Penetration enhancers, Adv Drug Deliv Rev 56(5), 603-618 (2004).
24. B.M. Magnusson, K.A. Walters and M.S. Roberts, Veterinary drug delivery: potential for skin penetration enhancement, Adv Drug Deliv Rev 50(3), 205-227 (2001).
25. J. Hadgraft and W.J. Pugh, The selection and design of topical and transdermal agents: a review, J Investig Dermatol Symp Proc 3(2), 131-135 (1998).
26. J.A. DeMartino, Z.D. Konteatis, S.J. Siciliano, R.G. Van, D.J. Underwood, P.A. Fischer and M.S. Springer, Arginine 206 of the C5a receptor is critical for ligand recognition and receptor activation by C-terminal hexapeptide analogs, J Biol Chem 270(27), 15966-15969 (1995).
27. T. Hoffmann, E.C. Bottger, H.P. Baum, R. Dennebaum, U. Hadding and D. Bitter-Suermann, Evaluation of low dose anaphylatoxic peptides in the pathogenesis of the adult respiratory distress syndrome (ARDS). Monitoring of early C5a effects in a guinea-pig in vivo model after i.v. application, Eur J Clin Invest 16(6), 500-508 (1986).
28. C. Lundberg, F. Marceau and T.E. Hugli, C5a-induced hemodynamic and hematologic changes in the rabbit. Role of cyclooxygenase products and polymorphonuclear leukocytes, Am J Pathol 128(3), 471-483 (1987).
29. G. Smedegard, L.X. Cui and T.E. Hugli, Endotoxin-induced shock in the rat. A role for C5a, Am J Pathol 135(3), 489-497 (1989).
30. M. Mohr, U. Hopken, M. Oppermann, C. Mathes, K. Goldmann, S. Siever, O. Gotze, H. Burchardi, Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis, Eur J Clin Invest 28(3), 227-234 (1998).
31. U. Hopken, M. Mohr, A. Struber, H. Montz, H. Burchardi, O. Gotze and M. Oppermann, Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies, Eur J Immunol 26(5), 1103-1109 (1996).
32. M. Huber-Lang, V.J. Sarma, K.T. Lu, S.R. McGuire, V.A. Padgaonkar, R.F. Guo, E.M. Younkin, R.G. Kunkel, J. Ding and R. Erickson, J.T. Curnutte, P.A. Ward, Role of C5a in multiorgan failure during sepsis, J Immunol 166(2), 1193-1199 (2001).
33. I.J. Laudes, J.C. Chu, S. Sikranth, M. Huber-Lang, R.F. Guo, N. Riedemann, J.V. Sarma, A.H. Schmaier and P.A. Ward, Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis, Am J Pathol 160(5), 1867-1875 (2002).
34. A.J. Short, N.J. Paczkowski, S.M. Vogen, S.D. Sanderson and S.M. Taylor, Response-selective C5a agonists: differential effects on neutropenia and hypotension in the rat, Br J Pharmacol 128(3), 511-514 (1999).
35. A.J. Strachan, I.A. Shiels, R.C. Reid, D.P. Fairlie and S.M. Taylor, Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist, Br J Pharmacol 134(8), 1778-1786 (2001).
36. H. Tagami, The role of complement-derived mediators in inflammatory skin diseases, Arch Dermatol Res 284, S2-9 (1992).
37. K. Bergh, O.J. Iversen and H. Lysvand, Surprisingly high levels of anaphylatoxin C5a des Arg are extractable from psoriatic scales, Arch Dermatol Res 285(3), 131-134 (1993).
38. U. Mrowietz, W.A. Koch, K. Zhu, O. Wiedow, J. Bartels, E. Christophers and J.M. Schroder, Psoriasis scales contain C5a as the predominant chemotaxin for monocyte-derived dendritic cells, Exp Dermatol 10(4), 238-245 (2001).
39. N.J. Paczkowski, A.M. Finch, J.B. Whitmore, A.J. Short, A.K. Wong, P.N. Monk, S.A. Cain, D.P. Fairlie and S.M. Taylor, Pharmacological characterization of antagonists of the C5a receptor, Br J Pharmacol 128(7), 1461-1466 (1999).